Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25189716 | 0.80 | KDM4E (0.45) | SMN1; SMN2HTTKDM4ELMNAP2RX7 | |
| SCHEMBL30361303 | 0.79 | HTT (0.42) | SMN1; SMN2HTTKDM4EGAALMNA | |
| SCHEMBL24129874 | 0.79 | HTT (0.43) | SMN1; SMN2HTTKDM4EGAALMNA | |
| SCHEMBL1432563 | 0.77 | HTT (0.43) | SMN1; SMN2HTTKDM4EGAAP2RX7 | |
| SCHEMBL24485756 | 0.76 | CNR2 (0.46) | SMN1; SMN2HTTKDM4EGAAALDH1A1 | |
| SCHEMBL4201013 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4EGAALMNAHPGD | |
| SCHEMBL25607515 | 0.72 | KMT2A (0.46) | SMN1; SMN2KDM4EGAALMNAALDH1A1 | |
| SCHEMBL24129873 | 0.72 | APLNR (0.41) | SMN1; SMN2HTTGAALMNAALDH1A1 | |
| SCHEMBL7521399 | 0.70 | LMNA (0.42) | SMN1; SMN2HTTGAALMNAHPGD | |
| SCHEMBL22518511 | 0.69 | SMN1; SMN2 (0.56) | SMN1; SMN2HTTKDM4EGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227435-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227435-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL2, IL23R | SMN1; SMN2 4542/4885HTT 2492/4885KDM4E 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.